Diarrhoea is the leading infectious cause of morbidity and death in children worldwide.
previous clinical trials have shown that GG ATCC 53013 (LGG) can be used to treat diarrhea.
, however, recent randomized controlled trials (RCTs) do not support the beneficial effects of LGG.
recently published in World J Gastroenterol, a meta-analysis showed that high-dose LGG therapy did reduce stool use and support treatment for acute diarrhea in children.
study looked at meta-analysis and RCTs evaluating children's use of acute diarrhea using LGG published by EMBASE, MEDLINE, PubMed, Web of Science Database and Cochrane Central Register of controlled Trials prior to April 2019.
to analyze the data using Coachane Review Manager.
results, which included 19 RDTs, showed that LGG did significantly reduce the duration of diarrhea in children compared to the control group (average difference (MD) -24.02 hours, 95% confidence interval (CI) (-36.58, -11.45)).
results of high-dose ≥1010 CFU/day treatment were better than low doses .MD -22.56 h, 95% CI (-36.41, -8.72).
similar effects in patients in Asia and Europe (MD -24.42 h, 95% CI (-47.01, -1.82); MD -32.02 h, 95% CI (-49.26, -14.79).
diarrhea time was reduced in LGG participants with less than 3 d at the time of entry into the group .MD -15.83 h, 95% CI (-20.68, -10.98).
high-dose LGG can effectively reduce the duration of diarrhea caused by rotovirus (MD -31.05 h, 95% CI (-50.31,-11.80)) and daily stools (MD -1.08,95% CI (-1.87,-0.28).
of the number and consistency of stools in the control group of lactic acid bacteria GG VS. the results of this meta-analysis show that high-dose LGG treatment can reduce the number of stools.
LGG treatment can reduce diarrhea time and the number of stools per day, and interventions are recommended at an early stage.